by Raynovich Rod | May 8, 2015 | 2025 Rayno Biopharmaceuticals Portfolio
Jobs Report Drive Stocks Higher-DOW Up 1.5% Stocks moved higher on the “goldilocks” job report which showed a gain of 223k added in April. The jobs number was too high to raise concerns about an increase in rates but not too bullish because overall...
by Raynovich Rod | May 1, 2015 | Biopharmaceuticals
Biotech Bounce-Caution on New Positions IBB up 2% at 340 support level Most biotech stocks are green as of early trading on May 1. Although the sector has taken a beating since April 23 most ETFs and funds are outperforming the market year to date up more than 10%. As...
by Raynovich Rod | Apr 28, 2015 | Biopharmaceuticals
Gilead (GILD) Gilead Beats Q1 Estimates: $7.4B Sales HCV , EPS $2.94, stock up 2% after hours XBI Down Another 4% Down 12.84% in Five Days Weak Tape and Sell-Off Continues…4/30…NASDAQ at 4991 XBI down 1.6% now at 2/24 lows at 212 High fliers hit with...
by Raynovich Rod | Apr 16, 2015 | 2025 Rayno Biopharmaceuticals Portfolio
Biotech Sector Moves Up In Tiny Steps Risk Remains On AACR Next Week Will Move Cancer Stocks Biotech indices and ETFs are trying to hit new highs but momentum is easing and trading is choppy. Nonetheless we are moving up from the brief correction near channel lows at...
by Raynovich Rod | Apr 8, 2015 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
4/13 Update Biotech Sector Uptrend Intact XBI at 232.09 Clovis Oncology (CLVS) Up 13% On Upgrade Biotech Sector Brings In Buyers The late Q1 sell-off appears over as buyers are coming in near the 5o day moving average of the XBI, the more volatile ETF.The IBB shows a...
by Raynovich Rod | Apr 7, 2015 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Teva Deal Expands Portfolio and Diagnostic Capabilities Adding RXDX to Rayno Small Cap Portfolio Ignyta, Inc. (RXDX) is an emerging biopharmaceutical Company targeting new oncology drugs that inhibit Tyrosine kinase receptors (Trk) with integrated biomarker-based...
by Raynovich Rod | Mar 30, 2015 | 2025 Rayno Biopharmaceuticals Portfolio
Global Rally Today But Healthcare Sector Lags A Bit DOW up 1.49% at 17,976 NASDAQ Up 1.15% at 4947 Healthcare up 0.93% We are in Day Two of the biotech rally that was sparked last Friday with the rumor supported by a Deutsche Bank analyst that Biomarin (BMRN) was a...
by Raynovich Rod | Mar 20, 2015 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Biotech and Healthcare ETFs Hit An All Time High–Another Rally Coming Today 3/20 M&A: Recent buy-outs of Cubist (CBST) for $9.5B and Pharmacyclics (PCYC) for $21B have raised the valuation bar. The healthcare sector remains strong and biopharmaceuticals are...
by Raynovich Rod | Mar 16, 2015 | 2024 Rayno Tools and Diagnostics Portfolio, 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
March 18-Stealth Rally With A Tempered Tape In Biotech NASDAQ up 0.92% Biotech stocks lagged the surprising FED rally today maybe because money was moving to other sectors.This bears close watching because only this week biotech stocks hit a new high.Money may be...
by Raynovich Rod | Mar 4, 2015 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Whoa! $261.25 And the winner is Abbvie (ABBV) for $21B! Pharmacyclics Buzz Is Back Biotech stocks covered the green screen today, despite a listless general market, driven by deal talk regarding Pharmacyclics (PCYC). Q4 2014 sales of their potential blockbuster drug...
